Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Feliza Mirasol is the science editor for 

Articles

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

Challenges, Innovations, and Future Outlook of Biologics Formulations

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The first needle-free adrenaline treatment launches in the UK, validating non-invasive delivery with real-world data comparable to injection effectiveness.

How ALK's UK-Approved Nasal Spray Changes the R&D Model for Acute Emergency Treatment

Take this quiz to test your comprehension of one of our recent feature articles.

Test Your Knowledge: Patient-Centric Care Through Oral Liquid Delivery

Test Your Knowledge (Answers): Patient-Centric Care Through Oral Liquid Delivery

 is Global Strategic Marketing Manager, Roquette.

, is Application and Innovation Technical Service Manager, Roquette.

The growing demand for liquid medicines is increasingly driven by the unique needs of several distinct patient groups, improving compliance in these demographics through flexible, palatable dosing options.

Enhancing Patient-Centric Care Through Oral Liquid Drug Delivery Formulations

CDC panel shifts vaccine policy by discouraging combined MMRV shot for young children due to increased febrile seizure risk.

CDC Panel’s Vote Separates MMRV Shot and What That Means

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet

Survey responses indicate that bio/pharma faces tariff-driven rising costs and supply strain, with firms aiming to boost compliance and diversification and seeking stable trade and R&D support.

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Based on an analysis done by the European Medicines Agency on the feasibility of alternatives, the European Commission maintains use of titanium dioxide in drug products.

In Europe, the Use of Titanium Dioxide in Drugs Will Continue

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

New manufacturing methods are being explored, but challenges are still present in personalized medicine development.